Bio-Rad Laboratoriesvs.Natera
BIO vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 4.9× larger than Bio-Rad Laboratories by market cap; year to date, Natera leads (+17.8% vs −2.3%).
Side by side
| BIO | NTRA | |
|---|---|---|
| Market cap | $8B | $38.8B |
| Price | $296.11 | $269.95 |
| Today | −0.4% | −4.2% |
| Return YTD | −2.3% | +17.8% |
| Return 1Y | +13.9% | +65.2% |
| P/E | 47.1 | — |
| P/S | 3.1 | 15.5 |
| P/B | 1.2 | 21.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Bio-Rad LaboratoriesBIO
American manufacturer of products for clinical diagnostics and life science research — including blood typing and droplet digital PCR.
Full BIO profile →NateraNTRA
Molecular and genetic diagnostics across prenatal screening, oncology and transplantation.
Full NTRA profile →More comparisons in Diagnostics
See where BIO and NTRA sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →